AMAna I. Moreno-Manuel

Ana I. Moreno-Manuel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana I. Moreno-Manuel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A TMEM175 Mutation Disrupts the Lysosomal-Mitochondrial Axis Causing Short QT Syndrome and Sudden Cardiac Death

    by Juan Manuel Ruiz-Robles, Isabel Martínez-Carrascoso, Álvaro Macías, Ana I. Moreno-Manuel, Patricia Sánchez-Pérez, Marre E. Corver, Paula G. Socuéllamos, Amaia Talavera-Gutiérrez, Francisco J. Bermúdez-Jiménez, Eva Cabrera-Borrego, et al.

    Short QT Syndrome (SQTS) is a rare cardiac channelopathy characterized by abnormally short QTc intervals and increased sudden cardiac death (SCD) risk. Only 20-30% of SQTS cases have been linked to genetic mutations, typically in surface membrane ion channels. We identified a novel lysosomal TMEM175 gene mutation (p.Arg377His) in 7 patients in a family with SQTS and SCD. Genetic analyses, including whole exome sequencing in the family and rare-variant burden testing in ∼118,000 UK Biobank participants, suggested an association between TMEM175 rare variants and QT interval shortening. Functional studies in CRISPR-engineered mice and patient-specific induced pluripotent stem cellderived cardiomyocytes (iPSC-CMs) revealed that TMEM175 R377H causes shortened QT intervals and hastened repolarization, respectively, as well an increased arrhythmia susceptibility. Isolated TMEM175 R377H cardiomyocytes showed action potential duration (APD) abbreviation, confirmed in whole TMEM175 R377H mouse hearts and patient-specific iPSC-CM monolayers. In silico and electron microscopy studies showed that TMEM175 R377H disrupts lysosomal-mitochondrial interactions, leading to mitochondrial dysfunction, as evidenced by the reduced maximal respiration and spare respiratory capacity, with reduced ATP production, I KATP activation, and APD shortening. This mutation represents the first non-sarcolemmal ion channel defect associated with SQTS and high SCD risk, potentially expanding the genetic landscape of the disease.

  • Open Access

    Repurposing polyamines to prevent life-threatening arrhythmias in Short QT Syndrome type 3

    by Ana I. Moreno-Manuel, Francisco M. Cruz, Álvaro Macías, Eva Cabrera-Borrego, José Jalife

    Short QT Syndrome type 3 (SQTS3) is an inherited disorder marked by an abnormally short QT interval on ECG and a high risk of life-threatening arrhythmias, for which effective targeted therapies are lacking. SQTS3 is caused by Kir2.1 mutations that enhance the outward component of the strong inward rectifier potassium current (IK1), disrupting its normal voltage-dependent regulation and severely abbreviating the cardiac action potential. Using a mouse model of SQTS3 carrying the Kir2.1M301K mutation, we examine whether administration of polyamines, the fundamental blockers of Kir2.1 channels, could restore the normal QT interval and prevent arrhythmia. Male mutant mice display reduced IK1 rectification, reduced sodium channel function, QT interval shortening, and a high susceptibility to induced ventricular tachycardia. Here, we show that systemic polyamine administration restores strong IK1 rectification, rescues sodium current density, prolongs action potential duration and QT interval, and significantly reduces arrhythmia inducibility, identifying a potential therapeutic approach for SQTS, a life-threatening disease.

  • Open Access

    Risk Stratification of Arrhythmogenic Consequences of Andersen-Tawil Syndrome Affecting Kir2.1-PIP2 Interactions

    by Lilian K. Gutiérrez, Francisco Miguel Cruz, Álvaro Macías, Ana I. Moreno-Manuel, Patricia Sánchez-Pérez, María Linarejos Vera-Pedrosa, Fernando Martínez de Benito, Aitor Díaz-Agustín, Juan Pablo Ochoa, Juan Manuel Ruiz, et al.

    Background: Andersen-Tawil syndrome type 1 (ATS1) is caused by loss-of-function mutations in KCNJ2 , which encodes the inward rectifier K + channel Kir2.1, a key determinant of I K1 . Impaired Kir2.1 destabilizes membrane excitability and predisposes to ventricular arrhythmias. Most ATS1 variants disrupt channel regulation by phosphatidylinositol 4,5-bisphosphate (PIP2), but whether specific mutations confer differential arrhythmic risk remains unclear. Objective: To determine whether ATS1 variants disrupting Kir2.1–PIP2 interactions define distinct arrhythmic risk profiles and establish a mechanistically informed framework for risk stratification. Methods: We performed a pooled patient-level analysis of 225 ATS1 patients carrying KCNJ2 variants impairing Kir2.1-PIP2 interaction. Inclusion of 22 clinical and electrocardiographic variables were used to identify mutation-specific risk profiles and predictors for arrhythmia risk. The approach was validated in a multicenter cohort of 20 ATS1 patients. Functional validation was performed using patient-derived iPSC-CMs, cardiac-targeted mouse models, and structural in silico analyses. Results: ATS1 variants segregated into three discrete clusters corresponding to high-, intermediate-, and low-risk arrhythmic phenotypes, establishing a mutation-dependent hierarchy of arrhythmic risk. Regression analyses identified six variables independently associated with severe arrhythmic outcomes. In patient-derived Patient-derived iPSC-CM demonstrated graded impairment of electrical propagation and arrhythmia susceptibility, with a hierarchy in CV (Control > R82W > R218W > G215D). ATS1 mouse models reproduced the clinical risk stratification. Structural modeling showed that high-risk variants localize near the channel pore and disrupt Kir2.1–PIP2 interactions through mutation-specific mechanisms. Conclusions: ATS1 caused by Kir2.1–PIP2–disrupting variants is not a uniform disorder but comprises biologically distinct subgroups with predictable differences in arrhythmic severity. Integrating genetics, functional phenotyping, and structural modeling provides a mechanistically grounded framework for ATS1 risk stratification and precision therapy development.

  • Open Access

    MOG1 L18F -mediated increase in late sodium current produces Long QT Syndrome

    by Paula G. Socuéllamos, Juan Manuel Ruiz-Robles, Francisco Miguel Cruz, Álvaro Macías, Alba Vera-Zambrano, Ana I Moreno-Manuel, Carmen Prior, Antonio J. Cartón, Carmen Valenzuela, José Jalife

    Background: Na V 1.5 channels, encoded by SCN5A , are essential for the genesis and shaping of the cardiac action potential (AP). Gain-of-function (GoF) variants in SCN5A are associated with long QT syndrome (LQTS), whereas loss-of-function (LoF) mutations are linked with Brugada syndrome. MOG1 is an integral part of the Na V 1.5 channelosome, increasing both current and membrane expression of Na V 1.5. Two LoF variants in MOG1 (E61X and E83D) cause Brugada Syndrome in patients, but no association with LQTS has been reported. Methods: We identified the first variant of unknown significance (VUS) in MOG1 (g.52C>T; p.18L>F) in a proband with LQTS. We generated AAV9-mediated cardiac-specific mouse models expressing MOG1 WT and MOG1 L18F . We performed surface ECG, programmed electrical stimulation in live mice, optical mapping in intact hearts, and patch-clamping, Ca 2+ dynamics and molecular biology assays in ventricular cardiomyocytes and HEK293 cells. Results: Clinical data from the MOG1 L18F proband revealed complete AV block, prolonged QT intervals, and non-sustained ventricular tachycardia (nsVT) under hypokalemia. MOG1 L18F mice recapitulated the patient’s phenotype, with QT prolongation and an increased incidence of arrhythmia, which worsened upon hypokalemia. Voltage-clamp recordings revealed a marked increase in the late sodium current ( I NaL ) in MOG1 L18F , accompanied by Na V 1.8 expression enhancement in the sarcolemma. In current-clamp and optical mapping experiments, action potential duration (APD) increased dramatically at low stimulation frequencies resulting in a very steep APD restitution curve in MOG1 L18F ventricular cardiomyocytes. This was associated with a high incidence of early and delayed afterdepolarizations (EADs and DADs, respectively) and triggered activity. Notably, the cellular electrophysiological effects of MOG1 L18F were reversed by the Na V 1.8 inhibitor A-803467, which also abridged the QT prolongation and reduced the arrhythmia inducibility in MOG1 L18F mice, with no effect in MOG1 WT mice. Conclusion: We have uncovered a new genetic basis for LQTS. Our findings demonstrate that the MOG1 L18F variant impairs AV conduction, increases I NaL , opposes repolarizing currents, and prolongs both action potential duration and the QT interval, ultimately leading to ventricular arrhythmias, particularly under hypokalemic conditions. As Na V 1.8 mediates the pathogenic I NaL increase and interacts with both MOG1 and Na V 1.5, it emerges as a promising therapeutic target.

  • Open Access

    Repurposing polyamines to prevent arrhythmias in Short QT Syndrome type 3, a potentially lethal disease

    by Ana I. Moreno-Manuel, Francisco M. Cruz, Álvaro Macías, Eva Cabrera-Borrego, José Jalife

    Short QT Syndrome type 3 (SQTS3) is a channelopathy characterized by the abbreviation of the QT interval on electrocardiogram and life-threatening arrhythmias. SQTS3 is caused by gain-of-function mutations in KCNJ2 , which codes the strong inward rectifier potassium channel Kir2.1 responsible for the repolarizing current I K1 . Inward- going rectification of I K1 is due to a voltage-dependent block by intracellular magnesium and polyamines. We evaluated the therapeutic potential of extrinsic polyamine administration to restore normal cardiac repolarization and prevent life-threatening arrhythmias in an AAV9-mediated mouse model of SQTS3 carrying the Kir2.1 M301K mutation, which shortens the QT interval to a minimum of 194ms in patients. Compared to Kir2.1 WT , the QT interval was significantly shortened in Kir2.1 M301K mice. Intracardiac stimulation induced long-lasting, high-frequency ventricular tachycardia. Patch-clamping demonstrated an extremely abbreviated action potential duration (APD) in Kir2.1 M301K cardiomyocytes due to a Kir2.1 lack of inward rectification. These I K1 defects decreased I Na density and Na V 1.5 expression. The mechanistically targeted Kir2.1 blockage by exogenous polyamines (spermine intraperitoneally or spermidine orally) prolonged the APD and the QT interval, and significantly reduced arrhythmia inducibility in Kir2.1 M301K mice. Polyamines significantly reduced the I K1 gain-of-function, an effect that alleviated the I Na reduction in mutant cardiomyocytes. Therefore, repurposing polyamine administration might be a novel and effective therapeutic strategy for managing cardiac arrhythmias in SQTS3 patients.


  • Open Access

    Ion channel traffic jams: the significance of trafficking deficiency in long QT syndrome

    by Gema Mondéjar-Parreño, Ana I. Moreno-Manuel, Juan Manuel Ruiz-Robles, José Jalife

    A well-balanced ion channel trafficking machinery is paramount for the normal electromechanical function of the heart. Ion channel variants and many drugs can alter the cardiac action potential and lead to arrhythmias by interfering with mechanisms like ion channel synthesis, trafficking, gating, permeation, and recycling. A case in point is the Long QT syndrome (LQTS), a highly arrhythmogenic disease characterized by an abnormally prolonged QT interval on ECG produced by variants and drugs that interfere with the action potential. Disruption of ion channel trafficking is one of the main sources of LQTS. We review some molecular pathways and mechanisms involved in cardiac ion channel trafficking. We highlight the importance of channelosomes and other macromolecular complexes in helping to maintain normal cardiac electrical function, and the defects that prolong the QT interval as a consequence of variants or the effect of drugs. We examine the concept of “interactome mapping” and illustrate by example the multiple protein–protein interactions an ion channel may undergo throughout its lifetime. We also comment on how mapping the interactomes of the different cardiac ion channels may help advance research into LQTS and other cardiac diseases. Finally, we discuss how using human induced pluripotent stem cell technology to model ion channel trafficking and its defects may help accelerate drug discovery toward preventing life-threatening arrhythmias. Advancements in understanding ion channel trafficking and channelosome complexities are needed to find novel therapeutic targets, predict drug interactions, and enhance the overall management and treatment of LQTS patients.


  • Open Access

    Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in Andersen Tawil Syndrome

    by Francisco M. Cruz, Ana I. Moreno-Manuel, Sánchez Pérez Patricia, Juan Manuel Ruiz-Robles, Paula García Socuellamos, Lilian K. Gutiérrez, María Linarejos Vera-Pedrosa, Amaia Talavera Gutierrez, Gema Mondéjar Parreño, Álvaro Macías, et al.

    Background: Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts. Methods and Results: Of 53 ATS1 patients reviewed from the literature, 54% responded partially to flecainide, with ventricular arrhythmia (VA) reduction in only 23%. Of the latter patients, VA persisted in 20-50%. Flecainide was ineffective in 23%, and surprisingly, 13.5% suffered a non-fatal cardiac arrest. In five cardiac-specific ATS1 mouse models (Kir2.1 Δ314–315 , Kir2.1 C122Y , Kir2.1 G215D and Kir2.1 R67W and Kir2.1 S136F ), flecainide or propafenone (40 mg/Kg i.p.) differentially prolonged the P wave, and the PR, QRS and QTc intervals compared to Kir2.1 WT ; Kir2.1 S136F had milder effects. Flecainide increased VA inducibility in all mutant mice except Kir2.1 S136F , which exhibited significant VA reduction. At baseline, Kir2.1 G215D cardiomyocytes had the lowest inward rectifier K+ channel (I K1 ) reduction, followed by Kir2.1 C122Y , Kir2.1 R67W and Kir2.1 S136F . Kir2.1 C122Y cardiomyocytes had a significant decrease in sodium inward current (I Na ). Flecainide (10 µM) slightly increased I K1 density in Kir2.1 WT and Kir2.1 S136F , while it decreased both I K1 and I Na in Kir2.1 C122Y and Kir2.1 R67W , despite normal trafficking of mutant channels. Optical mapping in ATS1 patient-specific iPSC-CM monolayers expressing Kir2.1 C122Y , Kir2.1 G215D and Kir2.1 R67W showed an increase in rotor incidence at baseline and under flecainide, confirming the druǵs proarrhythmic effect. Lastly, in-silico molecular docking predicts that the Kir2.1-Cys 311 pharmacophore-binding site is altered in Kir2.1 C122Y heterotetramers, reducing flecainide accessibility and leading to channel closure and arrhythmias. Conclusions: Class-Ic AADs are only partially effective and might be proarrhythmic in some ATS1 patients. Kir2.1 mutations impacting the resting membrane potential and cellular excitability create a substrate for life-threatening arrhythmias, raising significant concern about using these drugs in some ATS1 patients. CLINICAL PERSPECTIVE NOVELTY AND SIGNIFICANCE: What is known?: Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease caused by loss-of-function mutations in the KCNJ2 gene, which encodes the Kir2.1 channel responsible for the repolarizing, strong inwardly rectifying current I K1 . ATS1 treatment is empirical and subject to clinical judgment. It includes the use of class-Ic antiarrhythmic drugs (AADs), mainly flecainide, alone or in combination with β-adrenergic blocking drugs. However, pharmacological treatment is partial and might fail, leading to life-threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD) in some ATS1 patients. Some ATS1 mutations are known to disrupt the Kir2.1-Nav1.5 channelosome in mice and human iPSC-CMs, with consequent reductions in cardiac excitability and conduction velocity (CV), leading to VA, which may be exacerbated by flecainide. What new information does this article contribute?: In our analysis of 53 ATS1 patients, flecainide showed partial effectiveness. While a few patients experienced complete disappearance of VA, others had persistent arrhythmias and even suffered non-fatal cardiac arrest while on medication. In murine models expressing five relevant ATS1 mutations, flecainide or propafenone produced differential alteration in the P wave, PR, QRS and QTc intervals, and increased VA inducibility compared with Kir2.1 WT mice. Additionally, flecainide differentially affected I K1 and the Na + inward current (I Na ) current densities despite normal trafficking of mutant channels. In patient-specific induced pluripotent stem cell derived cardiomyocyte (iPSC-CM) monolayers flecainide reduced CV and increased rotor incidence, confirming the drugś proarrhythmic effect. In-silico molecular docking studies predicted that the Cys 311 pharmacophore binding site and flecainide accessibility are altered in mutated Kir2.1 channels, leading to premature channel closure and arrhythmias. We conclude that class-Ic AADs are only partially effective and might be proarrhythmic in some ATS1 patients. These findings raise concern about the use of class-Ic AADs in ATS1 patients and highlight the need for further studies to guide personalized therapy.


  • Extracellular Kir2.1 C122Y Mutant Upsets Kir2.1-PIP2 Bonds and Is Arrhythmogenic in Andersen-Tawil Syndrome

    by Francisco M. Cruz, Álvaro Macías, Ana I. Moreno-Manuel, Lilian K. Gutiérrez, María Linarejos Vera-Pedrosa, Isabel Martínez-Carrascoso, Patricia Sánchez Pérez, Juan Manuel Ruiz Robles, Francisco J. Bermúdez-Jiménez, Aitor Díaz-Agustín, et al.

    BACKGROUND: Andersen-Tawil syndrome type 1 is a rare heritable disease caused by mutations in the gene coding the strong inwardly rectifying K+ channel Kir2.1. The extracellular Cys (cysteine)(122)-to-Cys(154) disulfide bond in the channel structure is crucial for proper folding but has not been associated with correct channel function at the membrane. We evaluated whether a human mutation at the Cys(122)-to-Cys(154) disulfide bridge leads to Kir2.1 channel dysfunction and arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing its open state. METHODS: We identified a Kir2.1 loss-of-function mutation (c.366 A>T; p.Cys122Tyr) in an ATS1 family. To investigate its pathophysiological implications, we generated an AAV9-mediated cardiac-specific mouse model expressing the Kir2.1(C122Y) variant. We employed a multidisciplinary approach, integrating patch clamping and intracardiac stimulation, molecular biology techniques, molecular dynamics, and bioluminescence resonance energy transfer experiments. RESULTS: Kir2.1(C122Y) mice recapitulated the ECG features of ATS1 independently of sex, including corrected QT prolongation, conduction defects, and increased arrhythmia susceptibility. Isolated Kir2.1(C122Y) cardiomyocytes showed significantly reduced inwardly rectifier K+ (I-K1) and inward Na+ (I-Na) current densities independently of normal trafficking. Molecular dynamics predicted that the C122Y mutation provoked a conformational change over the 2000-ns simulation, characterized by a greater loss of hydrogen bonds between Kir2.1 and phosphatidylinositol 4,5-bisphosphate than wild type (WT). Therefore, the phosphatidylinositol 4,5-bisphosphate-binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch clamping, the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing phosphatidylinositol 4,5-bisphosphate concentrations. In addition, the Kir2.1(C122Y) mutation resulted in channelosome degradation, demonstrating temporal instability of both Kir2.1 and Na(V)1.5 proteins. CONCLUSIONS: The extracellular Cys(122)-to-Cys(154) disulfide bond in the tridimensional Kir2.1 channel structure is essential for the channel function. We demonstrate that breaking disulfide bonds in the extracellular domain disrupts phosphatidylinositol 4,5-bisphosphate-dependent regulation, leading to channel dysfunction and defects in Kir2.1 energetic stability. The mutation also alters functional expression of the Na(V)1.5 channel and ultimately leads to conduction disturbances and life-threatening arrhythmia characteristic of Andersen-Tawil syndrome type 1.


  • Open Access

    The Kir2.1E299V mutation increases atrial fibrillation vulnerability while protecting the ventricles against arrhythmias in a mouse model of short QT syndrome type 3

    by Ana I Moreno-Manuel, Álvaro Macías, Francisco M Cruz, Lilian K Gutiérrez, Fernando Martínez, Andrés González-Guerra, Isabel Martínez Carrascoso, Francisco José Bermúdez-Jimenez, Patricia Sánchez-Pérez, María Linarejos Vera-Pedrosa, et al.

    Short QT syndrome type 3 (SQTS3) is a rare arrhythmogenic disease caused by gain-of-function mutations in KCNJ2, the gene coding the inward rectifier potassium channel Kir2.1. We used a multidisciplinary approach and investigated arrhythmogenic mechanisms in an in-vivo model of de-novo mutation Kir2.1E299V identified in a patient presenting an extremely abbreviated QT interval and paroxysmal atrial fibrillation. We used intravenous adeno-associated virus-mediated gene transfer to generate mouse models, and confirmed cardiac-specific expression of Kir2.1WT or Kir2.1E299V. On ECG, the Kir2.1E299V mouse recapitulated the QT interval shortening and the atrial-specific arrhythmia of the patient. The PR interval was also significantly shorter in Kir2.1E299V mice. Patch-clamping showed extremely abbreviated action potentials in both atrial and ventricular Kir2.1E299V cardiomyocytes due to a lack of inward-going rectification and increased IK1 at voltages positive to −80 mV. Relative to Kir2.1WT, atrial Kir2.1E299V cardiomyocytes had a significantly reduced slope conductance at voltages negative to −80 mV. After confirming a higher proportion of heterotetrameric Kir2.x channels containing Kir2.2 subunits in the atria, in-silico 3D simulations predicted an atrial-specific impairment of polyamine block and reduced pore diameter in the Kir2.1E299V-Kir2.2WT channel. In ventricular cardiomyocytes, the mutation increased excitability by shifting INa activation and inactivation in the hyperpolarizing direction, which protected the ventricle against arrhythmia. Moreover, Purkinje myocytes from Kir2.1E299V mice manifested substantially higher INa density than Kir2.1WT, explaining the abbreviation in the PR interval. The first in-vivo mouse model of cardiac-specific SQTS3 recapitulates the electrophysiological phenotype of a patient with the Kir2.1E299V mutation. Kir2.1E299V eliminates rectification in both cardiac chambers but protects against ventricular arrhythmias by increasing excitability in both Purkinje-fiber network and ventricles. Consequently, the predominant arrhythmias are supraventricular likely due to the lack of inward rectification and atrial-specific reduced pore diameter of the Kir2.1E299V-Kir2.2WT heterotetramer.


  • Open Access

    Extracellular cysteine disulfide bond break at Cys122 disrupts PIP 2 -dependent Kir2.1 channel function and leads to arrhythmias in Andersen-Tawil Syndrome

    by Francisco Miguel Cruz, Álvaro Macías, Ana I I. Moreno-Manuel, Lilian K. Gutiérrez, María Linarejos Vera-Pedrosa, Isabel Martínez-Carrascoso, Patricia Sánchez Pérez, Juan Manuel Ruiz Robles, Francisco José Jose Bermúdez-Jiménez, Aitor Díaz-Agustín, et al.

    Background: Andersen-Tawil Syndrome Type 1 (ATS1) is a rare heritable disease caused by mutations in the strong inwardly rectifying K + channel Kir2.1. The extracellular Cys122-to-Cys154 disulfide bond in the Kir2.1 channel structure is crucial for proper folding, but has not been associated with correct channel function at the membrane. We tested whether a human mutation at the Cys122-to-Cys154 disulfide bridge leads to Kir2.1 channel dysfunction and arrhythmias by reorganizing the overall Kir2.1 channel structure and destabilizing the open state of the channel. Methods and Results: We identified a Kir2.1 loss-of-function mutation in Cys122 (c.366 A>T; p.Cys122Tyr) in a family with ATS1. To study the consequences of this mutation on Kir2.1 function we generated a cardiac specific mouse model expressing the Kir2.1 C122Y mutation. Kir2.1 C122Y animals recapitulated the abnormal ECG features of ATS1, like QT prolongation, conduction defects, and increased arrhythmia susceptibility. Kir2.1 C122Y mouse cardiomyocytes showed significantly reduced inward rectifier K + (I K1 ) and inward Na + (I Na ) current densities independently of normal trafficking ability and localization at the sarcolemma and the sarcoplasmic reticulum. Kir2.1 C122Y formed heterotetramers with wildtype (WT) subunits. However, molecular dynamic modeling predicted that the Cys122-to-Cys154 disulfide-bond break induced by the C122Y mutation provoked a conformational change over the 2000 ns simulation, characterized by larger loss of the hydrogen bonds between Kir2.1 and phosphatidylinositol-4,5-bisphosphate (PIP 2 ) than WT. Therefore, consistent with the inability of Kir2.1 C 122 Y channels to bind directly to PIP 2 in bioluminescence resonance energy transfer experiments, the PIP 2 binding pocket was destabilized, resulting in a lower conductance state compared with WT. Accordingly, on inside-out patch-clamping the C122Y mutation significantly blunted Kir2.1 sensitivity to increasing PIP 2 concentrations. Conclusion: The extracellular Cys122-to-Cys154 disulfide bond in the tridimensional Kir2.1 channel structure is essential to channel function. We demonstrated that ATS1 mutations that break disulfide bonds in the extracellular domain disrupt PIP 2 -dependent regulation, leading to channel dysfunction and life-threatening arrhythmias. CLINICAL PERSPECTIVE: NOVELTY AND SIGNIFICANCE: What is known? Andersen-Tawil Syndrome Type 1 (ATS1) is a rare arrhythmogenic disease caused by loss-of-function mutations in KCNJ2 , the gene encoding the strong inward rectifier potassium channel Kir2.1 responsible for I K1 . Extracellular Cys 122 and Cys 154 form an intramolecular disulfide bond that is essential for proper Kir2.1 channel folding but not considered vital for channel function. Replacement of Cys 122 or Cys 154 residues in the Kir2.1 channel with either alanine or serine abolished ionic current in Xenopus laevis oocytes. What new information does this article contribute? We generated a mouse model that recapitulates the main cardiac electrical abnormalities of ATS1 patients carrying the C122Y mutation, including prolonged QT interval and life-threatening ventricular arrhythmias. We demonstrate for the first time that a single residue mutation causing a break in the extracellular Cys122-to-Cys154 disulfide-bond leads to Kir2.1 channel dysfunction and arrhythmias in part by reorganizing the overall Kir2.1 channel structure, disrupting PIP2-dependent Kir2.1 channel function and destabilizing the open state of the channel. Defects in Kir2.1 energetic stability alter the functional expression of the voltage-gated cardiac sodium channel Nav1.5, one of the main Kir2.1 interactors in the macromolecular channelosome complex, contributing to the arrhythmias. The data support the idea that susceptibility to arrhythmias and SCD in ATS1 are specific to the type and location of the mutation, so that clinical management should be different for each patient. Altogether, the results may lead to the identification of new molecular targets in the future design of drugs to treat a human disease that currently has no defined therapy.